Pfizer gets Celebrex patent extension, sues generic companies

(Reuters) – U.S. regulators granted Pfizer Inc a reissued patent on its multibillion-dollar Celebrex pain drug that extends its marketing exclusivity until early December ...

AMAG Pharma gets FDA review on anemia drug

By Patricia Resende AMAG Pharmaceuticals (Nasdaq: AMAG) received word from the U.S. Food and Drug Administration that its supplemental new drug application (sNDA) has been accepted. The ...

Takeda execs scrambled after Actos cancer risks emerged, witness says

By Tracy Staton Actos and its potential links to bladder cancer are now on trial. And already, lawyers have brought out incriminating emails, in which Takeda Pharmaceutical executives ...

FDA panel looks askance at calcitonin bone drugs

By Tracy Staton New restrictions may be in store for a long-used set of bone-building drugs. Worried about a possible increase in cancer risk–and unconvinced of the drugs’ ...

Same song, lower budget for pharma’s sales force

By Tracy Staton The more things change, the more they stay the same. According to a new study from Johns Hopkins, that old adage applies to drug marketing. Spending on consumer advertising ...

Par to pay $45M for off-label Megace marketing

By Tracy Staton Par Pharmaceutical has joined the off-label rogue’s gallery. The drugmaker agreed to pay $45 million to wrap up charges that it promoted Megace ES, a treatment ...

Lilly CEO blasts Europe’s drug-pricing moves

By Tracy Staton European pricing policies aren’t popular in the drug industry. In fact, little these days is less popular–except, perhaps, patent expirations. Various ...

Antibiotics outfit Tetraphase offers price range for $75M biotech IPO

By Ryan McBride Tetraphase Pharmaceuticals hopes that the next phase for the biotech is as a public company. Toward that end, the Watertown, MA-based antibiotics developer plans an ...

Japan’s Ajinomoto pounces on Althea Tech in $175M buyout deal

By John Carroll Prowling the world’s markets for new buyouts, Japan‘s Ajinomoto has pounced on San Diego-based Althea Technologies, striking a deal to buy the biopharmaceutical ...

Tesaro pockets $91M in big financing as major cancer trials continue

By Ryan McBride With key results expected from its lead cancer program this year, the cancer drug specialist Tesaro ($TSRO) has stocked its coffers with $91.2 million from a public ...

TauRx adds $10.5M to its trove of unconventional Alzheimer’s PhIII cash

By John Carroll Singapore-based TauRx has reeled in $10.5 million from one of its unconventional investors, adding to the $300 million the company says it has already raised to back ...

Teva retrenches on troubled MS blockbuster hopeful as partner grabs $43M

By John Carroll Just as Active Biotech‘s big pharma partner Teva ($TEVA) enrolled the first person in its high-stakes gamble on the third big Phase III study for the oral MS ...
Page 2 of 5312345...102030...Last »
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS